Meine Merkliste
my.bionity.com  
Login  

2.786 Aktuelle Fachpublikationen von Future Medicine

rss

FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis

31.03.2015 | Cristina Lucía Dávila-Fajardo; Tahar van der Straaten; Rene Baak-Pablo; Catalina Medarde Caballero; Jose Cabeza Barr ..., Pharmacogenomics, 2015

Aim: The aim of our study was to explore the potential of FcGR genetic polymorphisms as a predictor of adalimumab efficacy in rheumatoid arthritis (RA) patients. Materials & methods: The study population was composed of 302 Dutch RA patients receiving adalimumab therapy. The FcGR2A (R131>H; ...

mehr

Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20+ B-cell lymphoma

31.03.2015 | Annegret Reichwagen; Marita Ziepert; Markus Kreuz; Ute Gödtel-Armbrust; Tanja Rixecker; Viola Poeschel; Mohammad Rez ..., Pharmacogenomics, 2015

Aim: To identify gene variants responsible for anthracycline-induced cardiotoxicity. Patients & methods: Polymorphisms of the NADPH oxidase subunits and of the anthracycline transporters ABCC1, ABCC2 and SLC28A3 were genotyped in elderly patients (61–80 years) treated for aggressive CD20+ B-cell ...

mehr

Evaluation of association studies and meta-analyses of MTHFR gene polymorphisms in colorectal cancer

31.03.2015 | Batoul Sadat Haerian; Monir Sadat Haerian, Pharmacogenomics, 2015

There is a discrepancy between the results of 89 original studies and 15 meta-analyses investigating the association of MTHFR rs1801133 and rs1801131 polymorphisms with colorectal cancer (CRC) risk. We examined this hypothesis through meta-analyses of both loci and their diplotypes as well as ...

mehr

Mechanistic insights into the effect of CYP2C9*2 and CYP2C9*3 variants on the 7-hydroxylation of warfarin

31.03.2015 | Addepalli Pavani; Shaik Mohammad Naushad; Balraj Alex Stanley; Renganathan Gnanambal Kamakshi; Krishnan Abinaya; Mal ..., Pharmacogenomics, 2015

Aim: To evaluate the impact of CYP2C9*2 and CYP2C9*3 variants on binding and hydroxylation of warfarin. Materials & methods: Multiple linear regression model of warfarin pharmacokinetics was developed from the dataset of patients (n = 199). Pymol based in silico models were developed for the ...

mehr

FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors

31.03.2015 | Ariana Montes; Eva Perez-Pampin; Beatriz Joven; Patricia Carreira; Antonio Fernández-Nebro; María del Carmen Ordóñez ..., Pharmacogenomics, 2015

Objectives: Reproducible association of a functional polymorphism in FCGR2A with response to a TNF inhibitor (TNFi) in patients with rheumatoid arthritis (RA) led us to explore other FcγR functional polymorphisms. Methods: Functional polymorphisms FCGR3A F158V, FCGR2B I223T and promoter VNTR in ...

mehr

Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity

31.03.2015 | Claudia Lanvers-Kaminsky; Jason A Sprowl; Ingrid Malath; Dirk Deuster; Maria Eveslage; Eberhard Schlatter; Ron HJ Ma ..., Pharmacogenomics, 2015

Aim: Assuming that genetic variants of the SLC22A2 and SLC31A1 transporter affect patients’ susceptibility to cisplatin-induced ototoxicity, we compared the distribution of 11 SLC22A2 variants and the SLC31A1 variant rs10981694 between patients with and without cisplatin-induced ototoxicity. ...

mehr

Polio vaccination: past, present and future

31.03.2015 | Ananda S Bandyopadhyay; Julie Garon; Katherine Seib; Walter A Orenstein, Future Microbiology, 2015

ABSTRACT  Live attenuated oral polio vaccine (OPV) and inactivated polio vaccine (IPV) are the tools being used to achieve eradication of wild polio virus. Because OPV can rarely cause paralysis and generate revertant polio strains, IPV will have to replace OPV after eradication of wild polio ...

mehr

Role of dermatology in pharmacogenomics: drug-induced skin injury

31.03.2015 | Riccardo G Borroni, Pharmacogenomics, 2015

Different individuals may respond diversely to the same drug, in terms of efficacy and toxicity. Adverse drug reactions cause about 6% of all hospital admissions and account for up to 9% of hospitalization costs. Drug-induced skin injury (DISI) is the most common presentation of adverse drug ...

mehr

Evaluation of a shared pharmacogenomics curriculum for pharmacy students

31.03.2015 | Kelly C Lee; Karen Suchanek Hudmon; Joseph D Ma; Grace M Kuo, Pharmacogenomics, 2015

Aim: This national dissemination study evaluated pharmacy students’ self-reported overall ability, self-efficacy and attitudes toward applying pharmacogenomics and perceptions of Pharmacogenomics Education Program, a shared pharmacogenomics curriculum. Patients & methods: Following a series of ...

mehr

Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients

31.03.2015 | Hye In Woo; Jung A Kim; Hyun Ae Jung; Ka-Kyung Kim; Ji Yean Lee; Jong-Mu Sun; Jin Seok Ahn; Keunchil Park; Soo-Youn ..., Pharmacogenomics, 2015

Aim: Pemetrexed is a commonly used chemotherapeutic agent for lung adenocarcinoma patients. We investigated the impact of the genetic polymorphisms on the therapeutic efficacy of pemetrexed in lung adenocarcinoma patients. Materials & methods: We performed genotying of 51 polymorphisms of 13 ...

mehr

Seite 2 von 279
Suche per e-Mail abonnieren

Sie erhalten passend zu Ihrer Suche die neusten Suchergebnisse per E-Mail. Dieser Service ist für Sie kostenlos und kann jederzeit abbestellt werden.

Ihr Bowser ist nicht aktuell. Microsoft Internet Explorer 6.0 unterstützt einige Funktionen auf Chemie.DE nicht.